RSV Preclinical Models in Respiratory Drug Development

by Virtus | Feb 4, 2026 | Viral & Rhinovirus Models, Uncategorized

RSV preclinical models are widely used in respiratory preclinical research to investigate viral pathogenesis, evaluate therapeutic efficacy, and support early stage respiratory drug development. Respiratory syncytial virus (RSV) is a significant cause of lower...

In Vivo Respiratory Studies in Preclinical Drug Development

by Virtus | Jan 6, 2026 | In Vivo Respiratory Studies, In Vivo Respiratory Studies

In vivo respiratory studies are a cornerstone of respiratory preclinical research and are widely used within translational programmes to support early stage respiratory drug development in the UK. Biotech and pharmaceutical sponsors frequently rely on invivo...

Human Rhinovirus Preclinical Models and Viral Challenge Studies in Respiratory Research

by Virtus | Jan 6, 2026 | Viral & Rhinovirus Models

Human rhinovirus preclinical models are increasingly used in preclinical antiviral model programmes to support respiratory drug development and mechanism-focused preclinical respiratory studies. Rhinovirus is one of the most common viral triggers linked to...

Preclinical Efficacy Testing in Respiratory Drug Development

by Virtus | Jan 6, 2026 | Respiratory Preclinical Research

Preclinical efficacy testing respiratory programmes rely on carefully selected experimental models to determine whether a candidate therapy produces measurable biological benefit before advancing into clinical studies. In respiratory drug development, early evidence...

Translational Respiratory Models in Early-Stage Drug Development

by Virtus | Jan 6, 2026 | Respiratory Preclinical Research

Translational respiratory models are a fundamental component of early stage respiratory drug development, enabling sponsors to bridge findings from preclinical respiratory studies with human disease biology. These models are widely used to evaluate mechanism of...